Zhejiang Wenda Pharma announces positive results from Phase II trial of NHWD-870 HCl oral BET inhibitor at the 2026 ESMO Annual Meeting

Summary

SHAOXING, China, 25 October 2026 — At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, a...